Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 8:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ER/PR+Her2neu Clear all
Recruiting Not applicable Interventional

Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery

NCT07206121
View directory record Official record
Conditions
Breast Cancer, Breast-conserving Surgery, Breast Cancer - Infiltrating Ductal Carcinoma, ER/PR+Her2neu, Grade I, II, III
Interventions
Radiofrequency ablation alone, Radiofrequency ablation Electrosurgical Device
Device
Lead sponsor
Innoblative Designs, Inc.
Industry
Eligibility
50 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 21, 2026, 8:24 PM EDT
Completed Phase 2 Interventional

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

NCT00134680
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Letrozole, Trastuzumab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Jul 21, 2026, 8:24 PM EDT
Not listed Phase 2 Interventional Results available

Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

NCT00499603
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, 5-Fluorouracil, Epirubicin, Cyclophosphamide, RAD001
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Jul 21, 2026, 8:24 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer

NCT00674206
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Jul 21, 2026, 8:24 PM EDT